Cytokinetics, Incorporated (CYTK) - What Are Investment Firms Saying About This Stock?

Key Points

• Analyst sentiment is broadly positive: 19 of 21 analysts rate CYTK a buy, giving it a consensus “Moderate Buy” rating and an average 12-month price target of $106.67.
• Quarterly results beat expectations: Cytokinetics reported a loss of $1.37 per share versus the $1.43 expected, while revenue of $47.56 million topped estimates of $41.88 million and rose sharply year over year.
• The stock has weakened despite institutional buying: Shares opened at $53.69, near their 52-week low of $53.55; several institutional investors increased their holdings, while insiders sold 180,926 shares worth about $12.5 million over the quarter.

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the twenty-one analysts that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nineteen have assigned a buy recommendation to the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $106.67.

CYTK has been the topic of several recent research reports. Royal Bank Of Canada lifted their target price on shares of Cytokinetics from $112.00 to $113.00 and gave the company an "outperform" rating in a report on Thursday, October 8th. HC Wainwright reiterated a "buy" rating and issued a $140.00 price target on shares of Cytokinetics in a report on Monday, October 19th. Weiss Ratings reissued a "sell (d-)" rating on shares of Cytokinetics in a research report on Thursday, October 15th. Morgan Stanley raised Cytokinetics from an "overweight" rating to a "buy" rating in a research report on Tuesday, September 1st. Finally, Citizens Jmp boosted their price objective on Cytokinetics from $105.00 to $110.00 and gave the stock a "market outperform" rating in a research note on Friday, August 7th.

Insider Activity

In related news, CEO Robert I. Blum sold 7,500 shares of the firm's stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $62.81, for a total transaction of $471,075.00. Following the sale, the chief executive officer directly owned 278,544 shares in the company, valued at approximately $17,495,348.64. This trade represents a 2.62% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Fady Malik sold 3,500 shares of the business's stock in a transaction that occurred on Tuesday, November 3rd. The stock was sold at an average price of $62.93, for a total value of $220,255.00. Following the transaction, the executive vice president directly owned 153,902 shares in the company, valued at $9,685,052.86. This trade represents a 2.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 180,926 shares of company stock worth $12,510,340. 2.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CYTK. Pictet Asset Management Holding SA increased its stake in Cytokinetics by 18.4% during the 3rd quarter. Pictet Asset Management Holding SA now owns 1,374,523 shares of the biopharmaceutical company's stock worth $90,569,000 after buying an additional 214,060 shares during the period. Principal Financial Group Inc. lifted its holdings in Cytokinetics by 11.9% in the 1st quarter. Principal Financial Group Inc. now owns 1,093,485 shares of the biopharmaceutical company's stock worth $72,072,000 after buying an additional 116,593 shares in the last quarter. Fisher Asset Management LLC boosted its position in Cytokinetics by 10.1% in the 3rd quarter. Fisher Asset Management LLC now owns 818,832 shares of the biopharmaceutical company's stock valued at $53,969,000 after buying an additional 75,135 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in Cytokinetics by 17.1% in the 1st quarter. ADAR1 Capital Management LLC now owns 632,556 shares of the biopharmaceutical company's stock valued at $41,692,000 after buying an additional 92,390 shares during the last quarter. Finally, Candriam S.C.A. grew its stake in shares of Cytokinetics by 39.3% during the third quarter. Candriam S.C.A. now owns 617,386 shares of the biopharmaceutical company's stock valued at $40,841,000 after acquiring an additional 174,320 shares in the last quarter.

Cytokinetics Stock Down 3.3%

Shares of CYTK stock opened at $53.69 on Friday. Cytokinetics has a fifty-two week low of $53.55 and a fifty-two week high of $88.31. The firm's 50 day moving average price is $65.68 and its two-hundred day moving average price is $69.97. The stock has a market cap of $6.68 billion, a price-to-earnings ratio of -8.89 and a beta of 0.45.

Cytokinetics (NASDAQ:CYTK - Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported ($1.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.43) by $0.06. The business had revenue of $47.56 million during the quarter, compared to analyst estimates of $41.88 million. During the same period in the previous year, the company earned ($2.55) EPS. Cytokinetics's revenue was up 2356.5% on a year-over-year basis. On average, equities analysts forecast that Cytokinetics will post -5.86 EPS for the current fiscal year.

Key Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Cytokinetics reported a third-quarter loss of $1.37 per share, narrower than the $1.43-per-share consensus loss, and revenue of $47.56 million versus expectations of $41.88 million. Revenue rose sharply year over year, and the loss narrowed from $2.55 per share a year earlier. Earnings results
• Positive Sentiment: RBC Capital Markets sees MYQORZO potentially driving a revenue inflection starting in 2027, supporting the longer-term growth case. RBC Capital Markets view
• Positive Sentiment: Analyst sentiment remained supportive: Morgan Stanley initiated a Buy view, while Citigroup raised its target to $105 and Leerink Partners set a new $100 target with an Outperform rating. Morgan Stanley rating Citigroup rating
• Neutral Sentiment: Leerink’s $100 target was reduced from $103, a modest cut that tempers the otherwise positive analyst news, though the firm maintained its Outperform rating. Leerink Partners rating

Cytokinetics Company Profile

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.